ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI…
Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs
Accomplished biotech and CRO leader brings 25+ years of global oncology drug…
Eisai Submits New Drug Application for Subcutaneous Formulation of LEQEMBI for the Treatment of Early Alzheimers Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in…
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc.…
KX-826: Redefining Confidence with Visible Hair Revival
HongKong, Nov. 21, 2025 (GLOBE NEWSWIRE) -- For millions struggling with thinning…
TraceLink Customers Demonstrate Readiness as DSCSA Dispenser Deadline Arrives
TraceLink Continues to Set the Standard for United States Drug Supply Chain…
INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community
Open-access resource includes Registry of Antiviral Compound Libraries to help catalyze drug…
Belite Bio Announces UKs Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
November 02, 2025 09:00 ET Â | Source: Belite Bio, Inc MHRA response…
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025 16:30 ET Â | Source: FibroBiologics, Inc. Advancing preparations to…
Bright Minds Biosciences toPresent at Upcoming Conferences
October 30, 2025 18:30 ET Â | Source: Bright Minds Biosciences NEW YORK,…